A medical marvel in the making, doctors at Northwestern University have successfully kept a man alive for 48 hours without lungs. The remarkable feat was made possible by an innovative custom machine designed by surgeon and researcher Ankit Bharat. The artificial lung system, called "flow-adaptive extracorporeal total artificial lung system" (TAL), breathed air into the patient's body while pumping out carbon dioxide.
The patient, a 33-year-old man who had contracted Influenza B complicated by a severe infection of Pseudomonas aeruginosa, was on the brink of death. The infections had rendered his lungs useless, and he was too sick for a transplant. However, with the TAL system, the doctors were able to keep him alive long enough to receive a new set of lungs.
The machine was an answer to the physiological puzzle that made bilateral pneumonectomy, the removal of both lungs, extremely risky before now. Normally, removing both lungs would lead to a massive pressure spike in the heart, causing it to fail within minutes.
To mitigate this risk, Bharat's team engineered the TAL system with four new components: a dual-lumen cannula that drained deoxygenated blood from the right side of the heart, a flow-adaptive shunt that recirculated excess blood back into the atrium, and two devices called dual left atrial return that returned oxygenated blood directly into the left atrium.
The patient was kept alive for 48 hours on this machine, during which time his septic shock began to resolve, and his medications were discontinued. When donor lungs became available, the team successfully performed a transplant, and after two years, the patient has returned to a normal, independent life with excellent lung function.
This breakthrough offers hope that patients who would otherwise be considered beyond medical help can be saved by innovative technologies. However, it also highlights the challenges of diagnosing irreversible damage in lung injuries and the need for more expertise and resources to make these advanced treatments accessible to all.
The patient, a 33-year-old man who had contracted Influenza B complicated by a severe infection of Pseudomonas aeruginosa, was on the brink of death. The infections had rendered his lungs useless, and he was too sick for a transplant. However, with the TAL system, the doctors were able to keep him alive long enough to receive a new set of lungs.
The machine was an answer to the physiological puzzle that made bilateral pneumonectomy, the removal of both lungs, extremely risky before now. Normally, removing both lungs would lead to a massive pressure spike in the heart, causing it to fail within minutes.
To mitigate this risk, Bharat's team engineered the TAL system with four new components: a dual-lumen cannula that drained deoxygenated blood from the right side of the heart, a flow-adaptive shunt that recirculated excess blood back into the atrium, and two devices called dual left atrial return that returned oxygenated blood directly into the left atrium.
The patient was kept alive for 48 hours on this machine, during which time his septic shock began to resolve, and his medications were discontinued. When donor lungs became available, the team successfully performed a transplant, and after two years, the patient has returned to a normal, independent life with excellent lung function.
This breakthrough offers hope that patients who would otherwise be considered beyond medical help can be saved by innovative technologies. However, it also highlights the challenges of diagnosing irreversible damage in lung injuries and the need for more expertise and resources to make these advanced treatments accessible to all.